Amarin (NASDAQ:AMRN) Releases Earnings Results

Amarin (NASDAQ:AMRN) issued its earnings results on Wednesday. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06), Zacks reports. Amarin had a negative return on equity of 2.99% and a negative net margin of 15.51%.

Here are the key takeaways from Amarin’s conference call:

• Positive Sentiment: International momentum accelerated, with in-market VASCEPA demand up 59% globally and 69% in Europe year over year. Recordati has launched in 11 European countries, while approvals in Singapore and South Korea are expected to support launches in 2027.
• Positive Sentiment: The U.S. business remains profitable and cash-generating despite generic pricing pressure. VASCEPA’s share of the icosapent ethyl market increased to 48% from 43% a year earlier, and branded prescriptions rose 14% in Q2.
• Positive Sentiment: Amarin generated $7 million of operating cash flow in Q2, its third consecutive positive quarter, and ended June with $314.6 million in cash and investments, no debt, and a $12 million improvement from year-end. Management continues to expect positive cash flow for full-year 2026.
• Positive Sentiment: The restructuring is complete and reduced operating expenses by 59% year over year, excluding restructuring charges by 38%, in line with the company’s approximately $70 million annual cost-savings target. Inventory also declined by $31.8 million from year-end, supporting working-capital discipline.
• Negative Sentiment: Total Q2 revenue fell to $42.2 million from $72.7 million, partly because the prior-year period included a $25 million Recordati upfront payment. Product revenue also declined to $39.1 million from $46.6 million, while higher volumes and the PBM relationship increased cost of goods sold by 22%.

Amarin Stock Performance

Shares of AMRN stock traded up $0.20 during mid-day trading on Wednesday, reaching $14.15. The company’s stock had a trading volume of 28,470 shares, compared to its average volume of 78,549. The firm’s 50-day moving average is $14.89 and its two-hundred day moving average is $14.89. Amarin has a 1-year low of $12.96 and a 1-year high of $20.90. The company has a market cap of $296.73 million, a P/E ratio of -21.77 and a beta of 0.80.

Institutional Trading of Amarin

A number of institutional investors and hedge funds have recently modified their holdings of AMRN. Two Sigma Investments LP grew its stake in Amarin by 1.8% in the third quarter. Two Sigma Investments LP now owns 60,071 shares of the biopharmaceutical company’s stock valued at $984,000 after acquiring an additional 1,047 shares during the period. Sei Investments Co. increased its stake in Amarin by 4.7% during the 3rd quarter. Sei Investments Co. now owns 29,212 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 1,299 shares in the last quarter. Banque Cantonale Vaudoise acquired a new stake in Amarin during the 3rd quarter worth approximately $32,000. Ameriprise Financial Inc. lifted its stake in Amarin by 13.1% in the third quarter. Ameriprise Financial Inc. now owns 17,376 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,008 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its holdings in shares of Amarin by 34.8% in the fourth quarter. Wells Fargo & Company MN now owns 9,254 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 2,390 shares during the period. 22.25% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amarin in a research note on Friday, July 17th. Zacks Research upgraded Amarin from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 16th. Finally, Wall Street Zen lowered shares of Amarin from a “buy” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy”.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics for cardiovascular health. Founded in 1993 and headquartered in Dublin, Ireland, the company is publicly traded on the NASDAQ under the ticker AMRN. Amarin’s primary mission is to improve cardiovascular outcomes through innovative lipid science and evidence-based therapies.

The company’s flagship product is Vascepa® (icosapent ethyl), a high-purity prescription omega-3 fatty acid approved for the treatment of severe hypertriglyceridemia and as an adjunct to statin therapy to reduce the risk of cardiovascular events.